

## Genome-wide association meta-analysis of PR interval identifies 47 novel loci associated with atrial and atrioventricular electrical activity

Jessica van Setten<sup>1</sup>, Jennifer A. Brody<sup>2</sup>, Yalda Jamshidi<sup>3</sup>, Brenton R. Swenson<sup>2,4</sup>, Anne M. Butler<sup>5</sup>, Harry Campbell<sup>6</sup>, Fabiola Del Greco M.<sup>7</sup>, Daniel S. Evans<sup>8</sup>, Quince Gibson<sup>9</sup>, Daniel F. Gudbjartsson<sup>10,11</sup>, Kathleen F. Kerr<sup>12</sup>, Bouwe P. Krijthe<sup>13</sup>, Leo-Pekka Lyytikäinen<sup>14,15,16</sup>, Christian Müller<sup>17</sup>, Martina Müller-Nurasyid<sup>18,19,20</sup>, Ilja M. Nolte<sup>21</sup>, Sandosh Padmanabhan<sup>22</sup>, Marylyn D. Ritchie<sup>23</sup>, Antonietta Robino<sup>24</sup>, Albert V. Smith<sup>25,26,27</sup>, Maristella Steri<sup>28</sup>, Toshiko Tanaka<sup>29</sup>, Alexander Teumer<sup>30,31</sup>, Stella Trompet<sup>32,33</sup>, Sheila Ulivi<sup>24</sup>, Niek Verweij<sup>34</sup>, Xiaoyan Yin<sup>35</sup>, David O. Arnar<sup>10,26,36</sup>, Folkert W. Asselbergs<sup>1,37,38</sup>, Joel S. Bader<sup>39</sup>, John Barnard<sup>40</sup>, Josh Bis<sup>2</sup>, Stefan Blankenberg<sup>17</sup>, Eric Boerwinkle<sup>41</sup>, Yuki Bradford<sup>23</sup>, Brendan M. Buckley<sup>42</sup>, Mina K. Chung<sup>43,44</sup>, Dana Crawford<sup>45</sup>, Marcel den Hoed<sup>46,47</sup>, Josh Denny<sup>48</sup>, Anna F. Dominiczak<sup>22</sup>, Georg B. Ehret<sup>49</sup>, Mark Eijgelsheim<sup>13,50</sup>, Patrick T. Ellinor<sup>51,52,53</sup>, Stephan B. Felix<sup>31,54</sup>, Oscar H. Franco<sup>13</sup>, Lude Franke<sup>55</sup>, Tamara B. Harris<sup>56</sup>, Hilma Holm<sup>10</sup>, Gandin Ilaria<sup>57</sup>, Annamaria Iorio<sup>58</sup>, Mika Kähönen<sup>59,60,61</sup>, Ivana Kolcic<sup>62</sup>, Jan A. Kors<sup>63</sup>, Edward G. Lakatta<sup>64</sup>, Lenore J. Launer<sup>56</sup>, Honghuang Lin<sup>35</sup>, Henry J. Lin<sup>65</sup>, Ruth J.F. Loos<sup>66,67</sup>, Steven A. Lubitz<sup>51,52,53</sup>, Peter W. Macfarlane<sup>68</sup>, Jared W. Magnani<sup>69</sup>, Irene Mateo Leach<sup>34</sup>, Thomas Meitinger<sup>70,71</sup>, Braxton D. Mitchell<sup>72</sup>, Thomas Munzel<sup>73</sup>, George J. Papanicolaou<sup>74</sup>, Annette Peters<sup>20,75,76</sup>, Arne Pfeufer<sup>77</sup>, Peter P. Pramstaller<sup>7,78</sup>, Olli T. Raitakari<sup>79,80,81</sup>, Jerome I. Rotter<sup>82</sup>, Igor Rudan<sup>6</sup>, Nilesh J. Samani<sup>83,84</sup>, David Schlessinger<sup>85</sup>, Claudia T. Silva Aldana<sup>86</sup>, Moritz F. Sinner<sup>19,20</sup>, Jonathan D. Smith<sup>43,87</sup>, Harold Snieder<sup>21</sup>, Elsayed Z. Soliman<sup>88</sup>, Timothy D. Spector<sup>89</sup>, David J. Stott<sup>22</sup>, Konstantin Strauch<sup>18,90</sup>, Kirill V. Tarasov<sup>64</sup>, Andre G. Uitterlinden<sup>91</sup>, David R. van Wageningen<sup>43,44</sup>, Uwe Völker<sup>31,92</sup>, Henry Völzke<sup>30,31</sup>, Melanie Waldenberger<sup>93,20,94</sup>, Harm Jan Westra<sup>55</sup>, Philipp S. Wild<sup>95,96</sup>, Tanja Zeller<sup>17</sup>, Alvaro Alonso<sup>97</sup>, Christy L. Avery<sup>98</sup>, Stefania Bandinelli<sup>99</sup>, Emelia J. Benjamin<sup>35</sup>, Francesco Cucca<sup>28</sup>, Marcus Dörr<sup>31,54</sup>, Luigi Ferrucci<sup>29</sup>, Paolo Gasparini<sup>24,57</sup>, Vilmundur Gudnason<sup>25,26</sup>, Caroline Hayward<sup>100</sup>, Susan R. Heckbert<sup>101</sup>, Andrew A. Hicks<sup>7</sup>, J. Wouter Jukema<sup>32,102,103</sup>, Stefan Käb<sup>19,20</sup>, Terho Lehtimäki<sup>14,15,104</sup>, Yongmei Liu<sup>105</sup>, Patricia B. Munroe<sup>106,107</sup>, Afshin Parsa<sup>108</sup>, Ozren Polasek<sup>62,109,110</sup>, Bruce M. Psaty<sup>111,112</sup>, Dan M. Roden<sup>113</sup>, Renate B. Schnabel<sup>114</sup>, Gianfranco Sinagra<sup>58</sup>, Kari Stefansson<sup>10,26</sup>, Bruno H. Stricker<sup>13,115,116</sup>, Pim van der Harst<sup>117,34,118</sup>, Cornelia M. van Duijn<sup>86</sup>, James F. Wilson<sup>6,100</sup>, Sina Gharib<sup>119\*</sup>, Paul I.W. de Bakker<sup>120,121\*</sup>, Aaron Isaacs<sup>122,123,124\*</sup>, Dan E. Arking<sup>125\*</sup>, Nona Sotoodehnia<sup>126\*</sup>

- 1 Department of Cardiology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands
- 2 Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA, USA
- 3 Cardiogenetics Lab, Molecular and Clinical Sciences Research Institute, St George's University of London, UK
- 4 Institute for Public Health Genetics, School of Public Health, University of Washington, Seattle, WA, USA
- 5 Division of infectious diseases, Washington University School of Medicine, St. Louis, MO
- 6 Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK

- 7 Institute for Biomedicine, Eurac Research, Bolzano, Italy, affiliated Institute of the University of Lübeck, Lübeck, Germany
- 8 California Pacific Medical Center Research Institute, San Francisco, CA, USA
- 9 Department of Surgery, University of Alabama Birmingham Hospital, Birmingham, AL, USA
- 10 deCODE genetics/Amgen, Inc., Reykjavik, Iceland
- 11 School of Engineering and Natural Sciences, University of Iceland, Reykjavik, Iceland
- 12 Department of Biostatistics, School of Public Health, University of Washington, Seattle, WA USA
- 13 Department of Epidemiology, Erasmus Medical Center, Rotterdam, The Netherlands
- 14 Department of Clinical Chemistry, Fimlab Laboratories, Tampere 33520, Finland
- 15 Department of Clinical Chemistry, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere 33014, Finland
- 16 Department of Clinical Chemistry, Fimlab Laboratories, Arvo Ylpön katu 34, D339, P.O. Box 100, FI-33014 Tampere, FINLAND
- 17 Department of General and Interventional Cardiology, University Heart Center Hamburg-Eppendorf, Germany, DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany
- 18 Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 19 Department of Medicine I, Ludwig-Maximilians-Universität, Munich, Germany
- 20 DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany
- 21 Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- 22 Institute of Cardiovascular and Medical Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, UK
- 23 Biomedical and Translational Informatics Institute, Geisinger, Danville PA
- 24 Institute for Maternal and Child Health - IRCCS "Burlo Garofolo", Trieste, Italy
- 25 Icelandic Heart Association, Kopavogur, Iceland
- 26 Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- 27 Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA
- 28 Istituto di Ricerca Genetica e Biomedica, Consiglio Nazionale delle Ricerche (CNR), Monserrato, Cagliari, Italy
- 29 Translational Gerontology Branch, NIA, Baltimore, MD, USA
- 30 Institute for Community Medicine, University Medicine Greifswald, Germany
- 31 DZHK (German Centre for Cardiovascular Research), partner site Greifswald 17475 Greifswald, Germany
- 32 Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands

- 33 Department of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
- 34 University Medical Center Groningen, University of Groningen, Department of Cardiology, the Netherlands
- 35 Department of Medicine, Boston University School of Medicine, Boston, MA, USA
- 36 Department of Medicine, Landspítali University Hospital, Reykjavik, Iceland
- 37 Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, the Netherlands
- 38 Institute of Cardiovascular Science, Faculty of Population Health Sciences, University College London, London, UK
- 39 Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA
- 40 Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
- 41 Human Genetics Center, University of Texas Health Science Center at Houston, Houston, Tx, USA
- 42 Department of Pharmacology and Therapeutics, University College Cork, Ireland
- 43 Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, Ohio, USA
- 44 Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA
- 45 Institute for Computational Biology, Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH.
- 46 Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
- 47 Science for Life Laboratory, Uppsala University, Uppsala, Sweden
- 48 Biomedical Informatics and Medicine, Vanderbilt University, Nashville, TN
- 49 Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 50 Department of Nephrology, University Medical Center Groningen, Groningen, The Netherlands
- 51 Program in Medical and Population Genetics, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 52 Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA
- 53 Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA, USA
- 54 Department of Internal Medicine B, University Medicine Greifswald
- 55 University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands
- 56 Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research Program, National Institutes of Health, Bethesda, Maryland, USA
- 57 Department of Medical Sciences, University of Trieste, Trieste, Italy

- 58 Cardiovascular Department, "Ospedali Riuniti and University of Trieste", Trieste, Italy
- 59 Department of Clinical Physiology, Tampere University Hospital, Tampere 33521, Finland
- 60 Department of Clinical Physiology, Finnish Cardiovascular Research Center - Tampere, Faculty of Medicine and Life Sciences, University of Tampere, Tampere 33014, Finland
- 61 Department of Clinical Physiology, Tampere University Hospital, Finn-Medi 1, 3th floor, P.O. Box 2000, FI-33521 Tampere, FINLAND
- 62 Faculty of Medicine, University of Split, Split, Croatia
- 63 Dept. of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands
- 64 Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA
- 65 The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
- 66 The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 67 The Mindich Child health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 68 Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
- 69 Department of Medicine, Division of Cardiology, University of Pittsburgh Medical Center Heart and Vascular Institute, University of Pittsburgh, Pittsburgh, PA, USA
- 70 Institute of Human Genetics, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 71 Institute of Human Genetics, Technische Universität München, Munich, Germany
- 72 Department of Medicine, University of Maryland School of Medicine and Geriatrics Research and Education Clinical Center, Baltimore VA Medical Center, MD, USA
- 73 Center for Cardiology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany; DZHK (German Center for Cardiovascular Research), partner site Rhine-Main, Mainz, Germany; Center for Translational Vascular Biology (CTVB), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
- 74 Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD, USA
- 75 Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
- 76 German Center for Diabetes Research, Neuherberg, Germany
- 77 MVZ für Molekulardiagnostik, Munich, Germany
- 78 Department of Neurology, Central Hospital, Bolzano, Italy
- 79 Department of Clinical Physiology and Nuclear Medicine, Turku University Hospital, Turku 20521, Finland

- 80 Research Centre of Applied and Preventive Cardiovascular Medicine, University of  
Turku, Turku 20014, Finland
- 81 Research Centre of Applied and Preventive Cardiovascular Medicine, University of  
Turku, P.O. Box 52, FI-20521 Turku, FINLAND
- 82 The Institute for Translational Genomics and Population Sciences, Departments of  
Medicine and Pediatrics, Los Angeles Biomedical Research Institute at Harbor-  
UCLA Medical Center, Torrance, CA, USA
- 83 Department of Cardiovascular Sciences, University of Leicester, Leicester, UK
- 84 NIHR Leicester Biomedical Research Centre, Leicester, UK
- 85 Laboratory of Genetics and Genomics, National Institute on Aging, National  
Institute of Health, Baltimore, MD, USA
- 86 Genetic Epidemiology Unit, Dept. of Epidemiology, Erasmus University Medical  
Center, Rotterdam, the Netherlands
- 87 Department of Cellular and Molecular Medicine Biology, Lerner Research Institute,  
Cleveland Clinic, Cleveland, Ohio, USA
- 88 Epidemiological Cardiology Research Center, Wake Forest School of Medicine,  
Winston-Salem, NC, USA
- 89 Department of Twin Research and Genetic Epidemiology, St Thomas Hospital,  
King's College London, UK
- 90 Chair of Genetic Epidemiology, IBE, Faculty of Medicine, LMU Munich, Germany
- 91 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The  
Netherlands
- 92 Interfaculty Institute for Genetics and Functional Genomics, University Medicine  
Greifswald
- 93 Research unit of Molecular Epidemiology, Helmholtz Zentrum München - German  
Research Center for Environmental Health, Neuherberg, Germany
- 94 Institute of Epidemiology II, Helmholtz Zentrum München - German Research  
Center for Environmental Health, Neuherberg, Germany
- 95 Preventive Cardiology and Preventive Medicine, Center for Cardiology, University  
Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
- 96 Center for Thrombosis and Hemostasis, University Medical Center of the  
Johannes Gutenberg-University Mainz, Mainz, Germany, DZHK (German Center  
for Cardiovascular Research), partner site Rhine-Main, Mainz, Germany
- 97 Department of Epidemiology, Rollins School of Public Health, Emory University,  
Atlanta, GA, USA
- 98 Department of Epidemiology and Carolina Population Center, University of North  
Carolina at Chapel Hill, Chapel Hill, NC, USA, 27514
- 99 Geriatric Unit, Azienda Sanitaria Firenze (ASF), Florence, Italy
- 100 Medical Research Council Human Genetics Unit, Institute of Genetics and  
Molecular Medicine, University of Edinburgh, Edinburgh, UK
- 101 Cardiovascular Health Research Unit and the Department of Epidemiology,  
University of Washington, Seattle, WA, USA
- 102 Einthoven Laboratory for Experimental Vascular Medicine, Leiden University  
Medical Center, Leiden, the Netherlands

- 103 Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands
- 104 Department of Clinical Chemistry, Fimlab Laboratories, Arvo Ylpön katu 34, D338, P.O. Box 100, FI-33014 Tampere, FINLAND
- 105 Department of Epidemiology and Prevention, Division of Public Health Sciences, Wake Forest University, Winston-Salem, NC, USA
- 106 Clinical Pharmacology, William Harvey Research Institute, Queen Mary University of London, London, UK
- 107 NIHR Biomedical Research Centre at Barts, Barts Health NHS Trust and Queen Mary University of London, London, UK
- 108 Department of Medicine, University of Maryland School of Medicine and Baltimore VA Medical Center, Baltimore, MD, USA
- 109 Psychiatric hospital "Sveti Ivan", Zagreb, Croatia
- 110 Gen-info Ltd, Zagreb, Croatia
- 111 Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, WA
- 112 Kaiser Permanente Washington Health Research Institute, Seattle, WA
- 113 Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University, Nashville, TN
- 114 Department of General and Interventional Cardiology, University Heart Center Hamburg-Eppendorf, Germany, DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/Lübeck, Germany,
- 115 Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
- 116 Inspectorate for Health Care, the Hague, The Netherlands
- 117 University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
- 118 Durrer Center for Cardiogenetic Research, ICIN-Netherlands Heart Institute, Utrecht, The Netherlands
- 119 Cardiovascular Health Research Unit, Division of Pulmonary Critical Care, Department of Medicine, University of Washington, Seattle, WA, USA
- 120 Department of Genetics, Center for Molecular Medicine, University Medical Center Utrecht, Utrecht, the Netherlands
- 121 Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, the Netherlands
- 122 CARIM School for Cardiovascular Diseases, Maastricht, The Netherlands
- 123 Center for Systems Biology (MaCSBio), Maastricht University, Maastricht, The Netherlands
- 124 Dept. of Biochemistry, Maastricht University, Maastricht, The Netherlands
- 125 McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
- 126 Cardiovascular Health Research Unit, Division of Cardiology, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, USA

\*Authors contributed equally to this work.

## ABSTRACT

Electrocardiographic PR interval measures atrial and atrioventricular depolarization and conduction, and abnormal PR interval is a risk factor for atrial fibrillation and heart block. We performed a genome-wide association study in over 92,000 individuals of European descent and identified 44 loci associated with PR interval (34 novel). Examination of the 44 loci revealed known and novel biological processes involved in cardiac atrial electrical activity, and genes in these loci were highly over-represented in several cardiac disease processes. Nearly half of the 61 independent index variants in the 44 loci were associated with atrial or blood transcript expression levels, or were in high linkage disequilibrium with one or more missense variants. Cardiac regulatory regions of the genome as measured by cardiac DNA hypersensitivity sites were enriched for variants associated with PR interval, compared to non-cardiac regulatory regions. Joint analyses combining PR interval with heart rate, QRS interval, and atrial fibrillation identified additional new pleiotropic loci. The majority of associations discovered in European-descent populations were also present in African-American populations. Meta-analysis examining over 105,000 individuals of African and European descent identified additional novel PR loci. These additional analyses identified another 13 novel loci. Together, these findings underscore the power of GWAS to extend knowledge of the molecular underpinnings of clinical processes.

## Introduction

The PR interval on the surface electrocardiogram reflects atrial and atrioventricular node myocyte depolarization and conduction. Abnormalities in PR interval duration are associated with increased risk of atrial fibrillation, which carries substantial risk of morbidity and mortality, and with cardiac conduction defects and heart block, conditions that often necessitate pacemaker implantation.<sup>1</sup> Understanding the molecular mechanisms underlying PR interval may provide insights into cardiac electrical disease processes, and identify potential drug targets for prevention and treatment of atrial fibrillation and conduction disease.

Twin and family studies suggest that the heritability of PR interval is between 40% and 60%.<sup>2</sup> Prior genome-wide association studies (GWAS) in up to 30,000 individuals have identified ten loci associated with PR interval among European-descent individuals.<sup>3,4</sup> The key motivation for the present study was to extend the biological and clinical insights derived from GWAS data by utilizing a >3 fold increased sample size to detect novel PR loci. We further increased power by performing trans-ethnic meta-analyses. To gain additional biological and clinical insights, we tested for pleiotropy with other clinically relevant phenotypes. We examined the biological and functional relevance of identified associations to gain insights into molecular processes underlying clinically important outcomes.



## Meta-analysis of Genome-Wide Association Studies for PR interval among European Ancestry Individuals

We meta-analyzed ~2.7 million single nucleotide polymorphisms (SNPs) from GWAS data on approximately 92,340 individuals of European ancestry from 31 studies (**Supplementary Table 1a and 1b**) for association with PR interval using an additive genetic model. A total of 1,601 SNPs mapping to 44 loci (of which 34 novel in Europeans) reached genome-wide significance ( $P \leq 5 \times 10^{-8}$ ) (**Figure 1, Table 1, Supplementary Figures 1 and 2**). While genomic inflation factor lambda was modest (1.11), linkage disequilibrium (LD) score regression<sup>5</sup> showed that deviation from the expected P-value distribution was mainly caused by true polygenicity (**Supplementary Figure 3**). Using a Bayesian gene-based test of association (GWiS),<sup>6</sup> we identified 61 independent signals in the 44 loci. For example, the top locus on chromosome 3, mapping to the two cardiac sodium channel genes *SCN5A* and *SCN10A*, had seven independent signals associated with PR interval (**Figure 2a**).

### Putative Functional Variants

To assess the functional relevance of the identified SNPs, we examined whether the index variants were in high LD with either nonsynonymous variants or with putative regulatory SNPs. Ten of the 44 loci had missense variants in high LD ( $r^2 > 0.8$ ) with the index SNP (**Table 1, Supplementary Table 3**). *TTN*, in particular, was enriched for missense SNPs, with the top signal and approximately one-third of the 47 genome-wide significant *TTN* SNPs being

missense (**Figure 2b**). To examine the possible impact of these amino acid substitutions on protein structure or function, we used two prediction algorithms, Sift<sup>7</sup> and PolyPhen-2<sup>8</sup>. The vast majority of the genome-wide significant missense variants at the 44 loci were categorized as tolerated by Sift and benign by PolyPhen-2, consistent with modest effects on PR interval not subjected to purifying selection (**Supplementary Table 3**).

Expression quantitative trait locus (eQTL) analysis suggests that index SNPs in half of the identified loci (22/44) are involved in *cis* gene regulation in at least one of the two tissue types examined at a false discovery rate (FDR) of <0.05 (**Supplementary Table 4**): left atrial appendage (n = 230 samples, 10 eQTL SNPs) and whole blood (n = 5311 samples, 16 eQTL SNPs). Several points are worth highlighting. First, for most of the 22 loci, the eQTL associations are for the gene nearest the index SNP, but for nearly one-third, they are not. Second, certain SNPs can be promiscuous in that they are associated with the transcript expression of multiple different genes. Third, despite substantially greater power to detect associations in whole blood compared to cardiac tissue due to markedly larger sample size, most of the eQTL associations found in cardiac atrial tissue – e.g. associations with *MEIS1* (**Supplementary Figure 4a**), *CAV1*, *FAT1*, and *TTN* transcripts – were not found in whole blood samples and appear to have some tissue-specificity. Two eQTL associations were found in both blood and cardiac tissue (*ADAM15* and *SENP2* (**Supplementary Figure 4b**)). While several other index SNPs were also associated with eQTLs in both tissue types, they were associated with transcript expression levels of different

genes. For instance, locus 17 SNP rs2732860 was associated with *TMEM182* expression in atrial tissue but with *MFSD9* expression in blood, again suggesting tissue-specificity for SNP–eQTL associations. Taken together, these data underscore the importance of examining eQTL data in tissue types relevant to the trait of interest: even with a modest study size of 230 cardiac atrial samples, a notable number of eQTL associations were uncovered.

The majority of loci (30/44) contain index SNPs that lie in, or are in high LD with, regulatory regions of the genome that are marked by deoxyribonuclease I (DNase I) hypersensitivity sites (DHSs), lending further support to the hypothesis that regulation of gene-expression plays an important role in determining PR interval (**Table 1**). To provide insight into the cellular and tissue structure of the phenotype, we examined *P*-values of all SNPs in the PR meta-analysis and assessed cell and tissue selective enrichment patterns of progressively more strongly associated variants to explore localization of signal within specific lineages or cell types. As would be expected for the cardiac phenotype of PR interval, we found enrichment of signal in cardiac DHSs compared with DHSs from other tissue types (**Supplementary Figure 5**). Interestingly, the second most enriched tissue DHSs were in those that regulate microvascular endothelial cells, complementing our findings (noted above) that there is enrichment in genes involved in blood vessel morphogenesis.

Using a candidate region approach in which we limited the regions examined only to those that contain cardiac DHSs (n=122,278), we identified an

additional four loci associated with PR interval after Bonferroni correction for the number of SNPs tested (**Table 2**).

### **Molecular Function and Biologic Processes associated with PR genes**

Although extensive LD among common variants and the incompleteness of the HapMap reference panel preclude an unambiguous identification of the functional variant or the culprit gene, we used the following criteria to implicate genes in 37 of the 44 loci: (1) the gene selected was the only nearby gene (within a  $\pm 500\text{kb}$  window); (2) the gene selected has a missense variant in high LD ( $r^2 > 0.8$ ) with the index SNP; or (3) the index SNP was associated with cardiac transcript expression levels of the selected gene (**Table 1**). The set of implicated genes, detailed in **Box 1**, showed strong enrichment in genes involved in cardiac development ( $P = 1.33 \times 10^{-15}$ ), specifically the cardiac chambers ( $P = 2.2 \times 10^{-11}$ ) and bundle of His ( $P = 6.69 \times 10^{-11}$ ) (**Supplementary Table 2**). Other notable biological processes include blood vessel morphogenesis ( $P = 7.32 \times 10^{-9}$ ) and cardiac cell differentiation ( $P = 1.79 \times 10^{-9}$ ). The molecular function and cellular component of the identified genes were largely enriched for transcription factors ( $P = 2.17 \times 10^{-6}$ ), ion-channel related genes ( $P = 1.02 \times 10^{-5}$ ), cell junction / cell signaling proteins ( $P = 4.40 \times 10^{-6}$ ), and sarcomeric proteins ( $P = 4.59 \times 10^{-5}$ ).

### **Clinical Relevance of PR-associated Loci**

To examine the clinical relevance of the identified loci, we intersected the PR genes with gene membership from multiple knowledge bases encompassing

over 4,000 human diseases. The most highly over-represented conditions ( $P \leq 1 \times 10^{-8}$ ) are heart diseases including congenital abnormalities and heart failure, sick sinus syndrome and sinus arrhythmia (phenotypes related to the sinus node which houses the pacemaker cells that generate heart beats), heart block (related to cardiac conduction between atria and ventricles), and atrial fibrillation (**Supplementary Table 5**). To further explore the molecular underpinnings of these clinical relationships, we jointly analyzed the PR GWAS results with the GWAS results of heart rate<sup>9</sup>, QRS interval (measure of ventricular conduction)<sup>10</sup>, and atrial fibrillation<sup>11</sup>.

We examined PR SNPs for association with QRS, atrial fibrillation, and heart rate. All 61 independent SNPs from 44 loci were examined. Over half of the independent SNPs (31/61) representing 20 loci were also associated with at least one of the other electrical phenotypes (**Supplementary Table 6, Figure 3**). The cardiac sodium channel genes, *SCN5A* and *SCN10A*, clearly play a critical role in cardiac electrophysiology. PR prolonging variants in these genes are also associated with prolonged QRS duration, but with lower risks for atrial fibrillation and lower heart rate (**Figure 3**). The role of transcription factors in cardiac electrophysiology is equally complex. Several T-box containing transcription factors, important for cardiac conduction system formation in the developing heart, are associated with PR interval. Although *TBX3* and *TBX5* sit close together on chromosome 12, the PR prolonging allele in *TBX5* prolongs QRS and decreases AF risk while the PR prolonging allele in *TBX3* shortens QRS duration while also decreasing AF risk. The PR prolonging variant near *TBX20* prolongs

QRS duration but is not associated with AF risk (**Figure 3**). Overall, eight of the 13 transcription factor genes associated with PR interval were also associated with at least one other atrial or atrioventricular electrical phenotype.

### **PR and QRS intervals**

Many loci regulate both atrial / atrioventricular (PR interval) and ventricular (QRS) depolarization and conduction: twelve of our 44 PR loci were nominally associated with QRS duration (**Supplemental Table 6**) and, similarly, 17 of 22 previously identified QRS loci were at least nominally associated with PR interval (**Supplementary Table 7**). Several intriguing findings are worth highlighting. First, while SNPs in most loci that are associated with prolonged PR are also associated with prolonged QRS, two loci have genome-wide significant discordant PR – QRS relationships, in which prolonged PR variants are associated with shorter QRS duration (*TBX3* and *SNORD56B*); **Supplementary Table 6, Figure 3, Supplementary Figure 6b**. Second, although *TBX20* plays a crucial role in the development of the cardiac conduction system, the SNPs that are associated with atrial and atrioventricular conduction (PR) differ from those related to ventricular conduction (QRS) (index SNP PR rs11763856, index SNP QRS rs1419856,  $r^2 = 0.001$ ). A better understanding of the influence of these specific regions on cardiac conduction will require further investigation.

## PR interval and Atrial Fibrillation

One-third (18/61) of PR index SNPs were nominally associated with AF. Of these 18 prolonged PR SNPs, six are associated with increased AF risk, whereas 12 paradoxically lowered AF risk. This observation is consistent with the relationship between PR interval and AF described in population studies, where we showed that while both short (<120 ms) and long (>200 ms) PR interval are associated with increased AF risk, short PR interval is associated with higher risk than long PR interval.<sup>11</sup> For both concordant (meaning relationships where the PR prolonging variant is associated with increased AF risk) and discordant PR – AF relationships, the larger the SNP effect size for PR interval, the larger the odds ratio for association with AF (**Supplementary Figure 6a**). The *CAV1* index SNP associated with increased PR interval and decreased AF risk reached genome-wide significance for both phenotypes. Furthermore, of 23 previously described AF GWAS loci, 11 were at least nominally associated with PR interval.<sup>12</sup> Interestingly, despite adequate power to identify modest associations, several loci, including *PITX2*, the most significant AF GWAS locus, showed no association with PR interval (**Supplementary Table 7**). Therefore, these loci may have a mode of action independent of atrial and atrioventricular depolarization or conduction.

## PR interval and Heart Rate

Ten PR loci were nominally associated with heart rate, including two sarcomeric proteins, *MYH6* and *TTN*. At the *MYH6* locus, variant rs365990 is

associated prolonged PR interval and with slower heart rates, whereas an independent *MYH6* signal (<20 kb away; rs11465506) also associates with prolonged PR but is associated with markedly faster heart rates. We then examined heart rate SNPs for association with PR and found half of the heart rate SNPs were associated with PR interval, with both concordant and discordant effects. Adjusting for heart rate in the regression model did not impact the effect size or significance of the PR-genotype associations, even though resting heart rate is modestly associated with PR interval (**Supplementary Figure 7**).

### **Joint phenotype meta-analyses**

Finally, we performed joint phenotype analyses, with PR-heart rate, PR-QRS, and PR-atrial fibrillation as outcomes, to increase the power of finding loci involved in cardiac electrical activity. As described above, prolonged PR variants can have either a concordant or discordant association with another electrical phenotype. Therefore, we modeled the outcome for each joint analysis in two ways: with a variant having a concordant effect on PR-QRS, PR-HR, and PR-AF, and a discordant effect (**Supplementary Figures 6a-c**). These analyses yielded 10 novel loci associated with atrial electrical activity: five related to atrial and ventricular conduction (from PR-QRS analyses); two related to atrial electrical activity and arrhythmias (from PR-AF analyses); two related to atrial depolarization and heart rate (from PR-HR analyses); and one related to both PR-QRS and PR-AF (**Table 2, Box 1, Supplementary Figure 8, Supplementary Table 8**). Additional support for association of several of these



loci were obtained by the DHS analysis, detailed above, and by trans-ethnic meta-analysis with African Americans, described below, lending further support to the validity of these associations (**Table 2, Supplementary Figure 8**).

### Trans-ethnic Analyses

Our study had less power to find associations among African Americans ( $n = 13,415$ ) than among European-descent individuals ( $n = 92,340$ ). Nonetheless, 16 of the 44 European-identified loci nominally replicated among African Americans, suggesting that a large proportion of genetic associations with PR interval are shared between the two ethnic groups (**Supplementary Table 7**). For European-descent GWAS PR SNPs at least nominally associated with PR among African Americans, the estimated effect was in the same direction for the two populations (**Supplementary Figure 6d**).

Examining only the index signal may underestimate the true number of locus associations that replicate. For instance, the *TBX5* locus index SNP rs6489953 is part of a large LD block associated with PR interval among individuals of European descent. This SNP is not significantly associated with PR interval among African Americans ( $\beta = 0.04$ ,  $P = 0.90$ , **Supplementary Table 6, Figure 2c**). There is, however, a very strong SNP-PR association signal in the *TBX5* among African Americans (index SNP rs7955405,  $\beta = 1.16$ ,  $P = 9.2 \times 10^{-16}$  in African Americans), **Figure 2c**. This SNP is in high LD with rs6489953 among European descent individuals (HapMap CEU  $r^2 = 0.62$ ), but not among populations from African descent (HapMap YRI  $r^2 = 0.03$ ). Hence, examination of

only the top European descent index signal would miss the association among African Americans. Furthermore, interrogation of the *TBX5* locus among African Americans narrows the association block, allowing for fine mapping of the association signal (**Figure 2c**). A second noteworthy interethnic difference is that there are SNP associations among those of European descent, for instance rs1896312 in *TBX3*, where despite adequate power, no association could be established among African Americans (**Figure 2c**).

Our trans-ethnic GWAS meta-analysis of PR interval among 13,415 African Americans and 92,340 European-ancestry individuals identified five additional novel loci associated with atrial and atrioventricular conduction (PR interval) (**Table 2, Supplementary Figure 8**).

## Discussion

Our GWAS meta-analytic study of over 92,000 individuals of European ancestry identified 44 loci associated with cardiac atrial and atrioventricular conduction (PR interval). The implicated genes at these loci show strong enrichment for genes involved in processes related to cardiac conduction, namely, cardiovascular system development and, specifically, in development of the cardiac chamber and bundle of His. Similarly, diseases overrepresented by these genes are processes related to arrhythmias and heart block, consistent with the current knowledge of the physiology and epidemiology of cardiac atrial conduction.

Using HapMap<sup>13</sup> imputation, we tested over 2.7 million SNPs, and while we did not directly test all common variants with this approach, nor did we test low-frequency variants (with minor allele frequencies below 1%), we identified many index SNPs in LD with functional variants, either through amino acid changes or involvement in gene regulation. For most newly identified loci, we are able to pinpoint a gene that may be causative, either because the index SNP (or a SNP in high LD with it) is a missense variant in the gene, or because it regulates the expression of the gene. Regulation of gene expression can be tissue specific, and our findings underscore the importance of examining eQTL data in tissue types relevant to the trait of interest.

A total of 34 novel loci were identified for PR interval in Europeans. Several have been identified previously in a related phenotype or in a different ancestral population, reassuring the validity of our results. Two loci, *EFHA1* and *LRCH1*, were previously identified for association with the PR segment.<sup>14</sup> In addition, the novel locus *CAMK2D* was found to associated with P-wave duration, and *MYH6* with P-wave duration and P-wave terminal force.<sup>15</sup> The *ID2* locus on chromosome 2 was found in a GWAS on PR interval in Hispanic/Latino populations.<sup>16</sup> A locus that was identified in two studies in Asian populations,<sup>17,18</sup> *SLC8A1*, did not reach genome-wide significance in our meta-analysis, but was suggestive with the strongest SNP being rs13026826 (beta for A-allele: 0.278,  $P=1.036 \times 10^{-6}$ ).

Contrasting meta-analyzed association results from European descent individuals with results from a smaller sample of African Americans, we find that, with few exceptions, a large proportion of genetic associations with PR interval are shared between the two ethnic groups. We then combined data from Europeans and African Americans in a trans-ethnic meta-analysis, allowing us to find additional loci. With over 105,000 samples in total, our power to find association – even with small effect sizes – was substantial for common variants. Future studies should examine sequence or other data that provide better assessment of rare and common functional variants, as was done previously for *SCN5A*.<sup>19</sup>

We also combined our results on PR interval with previously published results on heart rate, QRS duration, and atrial fibrillation, and identified loci contributing to atrial arrhythmias and atrioventricular conduction. We observed significant pleiotropy of effect of these SNPs, with over half of the SNPs associated with PR interval (atrial conduction) in the study also associated ventricular conduction (QRS interval), atrial arrhythmias (atrial fibrillation), and heart rate (RR interval).

Our series of GWAS studies, including transethnic and cross-trait meta-analytic studies, has identified 57 loci, 47 of which are novel, associated with cardiac atrial and atrioventricular electrical activity among individuals of European and African ancestry. Understanding the biology of a trait in this way provides

insight into related disease processes and may help identify potential approaches to drug therapy.

**Conflicts of interest:**


Dr. de Bakker is currently an employee of and owns equity in Vertex Pharmaceuticals.

## **References**

1. Kannel, W.B. & Benjamin, E.J. Current perceptions of the epidemiology of atrial fibrillation. *Cardiology clinics* **27**, 13-24, vii (2009).
2. Hanson, B. *et al.* Genetic factors in the electrocardiogram and heart rate of twins reared apart and together. *The American journal of cardiology* **63**, 606-9 (1989).
3. Pfeufer, A. *et al.* Genome-wide association study of PR interval. *Nature genetics* **42**, 153-9 (2010).
4. Holm, H. *et al.* Several common variants modulate heart rate, PR interval and QRS duration. *Nature genetics* **42**, 117-22 (2010).
5. Bulik-Sullivan, B.K. *et al.* LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nat Genet* **47**, 291-5 (2015).
6. Huang, H., Chanda, P., Alonso, A., Bader, J.S. & Arking, D.E. Gene-based tests of association. *PLoS genetics* **7**, e1002177 (2011).
7. Kumar, P., Henikoff, S. & Ng, P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. *Nature protocols* **4**, 1073-81 (2009).
8. Adzhubei, I.A. *et al.* A method and server for predicting damaging missense mutations. *Nature methods* **7**, 248-9 (2010).
9. Eijgelsheim, M. *et al.* Genome-wide association analysis identifies multiple loci related to resting heart rate. *Human molecular genetics* **19**, 3885-94 (2010).
10. van der Harst, P. *et al.* 52 Genetic Loci Influencing Myocardial Mass. *J Am Coll Cardiol* **68**, 1435-48 (2016).
11. Ellinor, P.T. *et al.* Meta-analysis identifies six new susceptibility loci for atrial fibrillation. *Nature genetics* **44**, 670-5 (2012).
12. Christophersen, I.E. *et al.* Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation. *Nat Genet* **49**, 946-952 (2017).
13. Frazer, K.A. *et al.* A second generation human haplotype map of over 3.1 million SNPs. *Nature* **449**, 851-61 (2007).
14. Verweij, N. *et al.* Genetic determinants of P wave duration and PR segment. *Circ Cardiovasc Genet* **7**, 475-81 (2014).
15. Christophersen, I.E. *et al.* Fifteen Genetic Loci Associated With the Electrocardiographic P Wave. *Circ Cardiovasc Genet* **10**(2017).
16. Seyerle, A.A. *et al.* Genome-wide association study of PR interval in Hispanics/Latinos identifies novel locus at ID2. *Heart* (2017).
17. Hong, K.W. *et al.* Identification of three novel genetic variations associated with electrocardiographic traits (QRS duration and PR interval) in East Asians. *Hum Mol Genet* **23**, 6659-67 (2014).
18. Sano, M. *et al.* Genome-wide association study of electrocardiographic parameters identifies a new association for PR interval and confirms previously reported associations. *Hum Mol Genet* **23**, 6668-76 (2014).

19. Magnani, J.W. *et al.* Sequencing of SCN5A identifies rare and common variants associated with cardiac conduction: Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. *Circ Cardiovasc Genet* **7**, 365-73 (2014).


## Figures




**Figure 1: Genome-wide results of PR interval in 92,000 individuals of European descent.** 2.8 million SNPs were tested for association with PR interval in 31 cohorts. The Manhattan plot shows the meta-analysis association results: 44 independent loci (labeled) are associated at the genome-wide significance level of  $P \leq 5 \times 10^{-8}$ , as marked by the dashed line.




### SCN5A-SCN10A




### TTN



### TBX5-TBX3



**Figures 2a-c: Regional association plots of specific loci associated with PR interval.** Each SNP is plotted with respect to its chromosomal location (x axis) and its P value (y axis on the left). The blue line indicates the recombination rate (y axis on the right) at that region of the chromosome. Blue outlined squares mark non-synonymous SNPs. Green triangles depict association results of the African Americans meta-analysis, only SNPs with  $P < 0.1$  are shown. (a) Locus 2 and 3 (*SCN10A-SCN5A*) on chromosome 3. The index SNPs for the two genes are named with their rs-numbers and highlighted with two different colors (blue and red). Other SNPs in linkage disequilibrium with the index SNP are denoted in the same color; color saturation indicates the degree of correlation with the index SNP. (b) Locus 19 (*TTN*) on chromosome 2; and (c) Locus 9 and 10 (*TBX5-TBX3*) on chromosome 12.



**Figure 3: Heatmap showing overlapping loci between four traits.** For each locus associated with PR interval, we tested strength of the association and direction of effect for three related traits: QRS duration, atrial fibrillation, and heart rate. While the genetic bases of these three traits show a distinct overlap with that of PR interval, we observe for each trait overlapping loci with both concordant and discordant associations, with some variants that prolong PR interval prolonging QRS duration or RR interval (concordant associations), whereas others shorten QRS duration or decrease RR interval. Similarly, some variants that prolong PR interval increase AF risk (concordant association) while others decrease AF risk (discordant).

## Tables

**Table 1: Description of novel and previously identified loci.** For each locus we list the number of independent signals, whether this locus is nominal significant in African Americans, if missense SNPs are in LD with the index SNP or SNPs, if the index SNP is in LD with or located in a cardiac DHS, and if the locus contains cardiac or blood eQTLs. Abbreviations: Chr - chromosome, CA - coded allele, CAF - coded allele frequency, SE - standard error.

European ancestry INDEX SNPs in previously identified PR loci									Indep Sig	AA PR	Missense	CardiacDHS	CardiaceQTL
Locus	SNP	Chr	Closest Gene	CA	CAF	Beta (ms)	SE (ms)	P-value	n	p<0.05	r <sup>2</sup> >0.8	r <sup>2</sup> >0.8	FDR<0.05
1	rs4430933	2	<i>MEIS1</i>	A	0.39	1.3	0.11	5.06E-30	1	YES	-	YES	<i>MEIS1</i>
2	rs6599250	3	<i>SCN10A</i>	T	0.41	3.8	0.11	4.42E-242	2	YES	<i>SCN10A</i>	YES	-
3	rs11708996	3	<i>SCN5A</i>	C	0.15	3.1	0.18	1.06E-68	5	YES	<i>SCN5A</i>	YES	-
4	rs343849	4	<i>ARHGAP24</i> <i>BNIP1</i> / <i>NKX2-5</i> /	A	0.30	-2.1	0.13	3.12E-61	1	YES	-	YES	-
5	rs255292	5	<i>CREBRF</i>	C	0.42	-1.1	0.12	5.99E-21	1	YES	-	YES	<i>CREBRF</i>
6	rs3807989	7	<i>CAV1</i> / <i>CAV2</i>	A	0.41	2.0	0.12	8.65E-69	1	YES	-	YES	<i>CAV1</i> & <i>CAV2</i>
7	rs652673	11	<i>WNT11</i> <i>C12orf67</i> /	C	0.22	-0.8	0.15	4.41E-08	1	-	-	-	-
8	rs17287293	12	<i>SOX5</i>	G	0.15	-2.2	0.16	2.33E-41	1	YES	-	-	-
9	rs1896312	12	<i>TBX3</i>	C	0.29	1.6	0.13	1.16E-34	4	-	-	-	-
10	rs6489953	12	<i>TBX5</i>	C	0.17	1.2	0.15	1.94E-16	2	-	-	-	-

European ancestry index SNPs in Novel PR loci									Indep Sig	AA PR	Missense	CardiacDHS	CardiacQTL
Locus	SNP	Chr	Closest Gene	CA	CAF	Beta	SE	P-value	n	p<0.05	r <sup>2</sup> >0.8	r <sup>2</sup> >0.8	FDR<0.05
11	rs4648819	1	<i>SKI</i>	G	0.11	-1.7	0.28	4.68E-10	1	-	-	-	-
12	rs7538988	1	<i>EPS15</i>	C	0.03	-2.1	0.37	1.14E-08	1	-	-	YES	-
13	rs12127701	1	<i>MYBPHL / SYPL2</i>	G	0.06	1.7	0.28	1.54E-09	1	-	<i>MYBPHL</i>	-	<i>MYBPHL &amp; SYPL2</i>
14	rs11264339	1	<i>ADAM15</i>	T	0.48	-0.7	0.11	5.94E-10	1	-	<i>EFNA1</i>	YES	<i>ADAM15 &amp; CLK2</i>
15	rs397637	1	<i>OBSCN</i>	T	0.28	0.8	0.12	7.11E-10	1	-	<i>OBSCN</i>	YES	-
16	rs3856447	2	<i>ID2</i>	A	0.39	1.2	0.11	1.20E-26	2	-	-	YES	-
17	rs2732860	2	<i>TMEM182</i>	G	0.52	-0.9	0.11	3.03E-15	2	-	-	YES	<i>TMEM182</i>
18	rs13018106	2	<i>FIGN</i>	C	0.42	-0.8	0.12	1.53E-11	1	YES	-	YES	-
19	rs922984	2	<i>TTN</i>	T	0.07	1.5	0.23	1.79E-11	2	-	<i>TTN</i>	YES	<i>TTN</i>
20	rs9826413	3	<i>EOMES</i>	T	0.06	2.0	0.36	1.69E-08	1	-	-	-	-
21	rs900669	3	<i>FRMD4B</i>	A	0.25	0.8	0.13	5.71E-09	1	YES	-	YES	-
22	rs13087058	3	<i>PDZRN3</i>	C	0.37	-1.0	0.12	5.82E-17	1	-	-	YES	<i>PDZRN3</i>
23	rs16858828	3	<i>PHLDB2</i>	C	0.18	0.9	0.15	2.41E-08	1	-	-	YES	-
24	rs6441111	3	<i>CCNL1</i>	C	0.52	0.8	0.13	6.96E-11	1	YES	-	YES	-
25	rs7638853	3	<i>SENP2</i>	A	0.34	-0.7	0.12	2.44E-08	1	-	<i>SENP2</i>	YES	<i>SENP2</i>
26	rs17446418	4	<i>CAMK2D</i>	G	0.26	0.8	0.13	3.41E-09	1	-	-	YES	-
27	rs3733409	4	<i>FAT1</i>	T	0.13	0.9	0.17	2.67E-08	1	YES	<i>FAT1</i>	YES	<i>FAT1</i>
28	rs7729395	5	<i>PAM</i>	T	0.05	2.4	0.37	1.00E-10	1	-	<i>PAM</i>	-	-
29	rs11763856	7	<i>HERPUD2</i>	T	0.03	3.1	0.49	4.47E-10	2	YES	-	YES	-
30	rs2129561	7	<i>MKLN1</i>	A	0.42	-1.0	0.12	3.39E-15	1	-	-	-	-
31	rs881301	8	<i>FGFR1</i>	C	0.41	0.8	0.12	5.04E-10	1	-	-	YES	-
32	rs12678719	8	<i>ZFPM2</i>	G	0.27	0.8	0.13	3.77E-10	1	-	-	-	-
33	rs12359272	10	<i>ALDH18A1 / SORBS1</i>	A	0.37	1.0	0.13	3.68E-16	2	-	-	YES	-
34	rs12257568	10	<i>SH3PXD2A /</i>	T	0.41	1.0	0.12	5.83E-18	2	YES	-	-	-

<i>OBFC1</i>													
35	rs1372797	11	<i>NAV2</i>	T	0.12	-1.1	0.18	2.36E-09	2	-	-	YES	-
36	rs11067773	12	<i>MED13L</i>	C	0.09	-1.3	0.23	1.02E-08	1	-	-	-	-
37	rs718426	13	<i>EFHA1</i>	G	0.41	-1.2	0.11	3.25E-24	1	-	-	YES	-
38	rs2585897	13	<i>XPO4</i>	A	0.16	1.2	0.15	9.28E-16	1	YES	-	YES	-
39	rs9590974	13	<i>LRCH1</i>	C	0.34	1.1	0.12	1.02E-19	1	-	-	YES	-
40	rs11465506	14	<i>IL25 / MYH6</i>	A	0.02	-6.4	1.04	7.06E-10	2	YES	<i>MYH6</i>	YES	-
41	rs4901308	14	<i>FERMT2</i> <i>SNORD56B</i>	T	0.19	-0.8	0.15	2.04E-08	1	-	-	-	-
42	rs17767398	14	<i>SIPA1L1</i>	G	0.26	1.0	0.13	6.44E-13	1	-	-	YES	-
43	rs904974	15	<i>TLE3</i>	T	0.16	1.1	0.19	4.53E-08	1	YES	-	-	-
44	rs1984481	17	<i>MYOCD</i>	C	0.54	-0.8	0.12	1.37E-11	1	-	-	YES	-

**Table 2: Novel loci identified by transethnic and pleiotropic meta-analyses.** We combined GWAS results of Europeans and African Americans and identified an additional five loci associated with PR interval. To identify loci associated with atrioventricular conduction, we combined data on PR interval with association results of QRS duration (six novel loci), of RR interval (two novel loci), and of atrial fibrillation (three loci). Furthermore, we tested SNPs in DHSs only, adjusting the significance threshold accordingly, and found another four SNPs significantly associated with PR interval. Because some of the loci overlapped, these analyses led to 13 novel loci in total.

Locus	SNP	Chr	Position	Closest Gene	Supporting Analysis	P-value						
						DHS	AA-EA Joint	PR QRS concordant	PR QRS discordant	PR AF concordant	PR AF discordant	PR RR concordant
45	rs2030569	3	66496608	<i>SLC25A26</i>	AA-EAJoint	-	2.539E-08	-	-	-	-	-
46	rs3732733	3	71286767	<i>FOXP1</i>	DHS; AA-EAJoint	1.247E-07	4.837E-08	-	-	-	-	-
47	rs2970852	4	23430621	<i>PPARGC1A</i>	DHS; PR-QRSConcordant	5.600E-08	-	7.547E-09	-	-	-	-
48	rs1254724	6	2525198	<i>C6orf195</i>	DHS; PR-QRSDiscordant; PR-AFDiscordant	7.716E-08	-	-	4.264E-08	-	1.163E-08	-
49	rs11970286	6	118787067	<i>SLC35F1</i>	AA-EAJoint; PR-AFConcordant	-	4.166E-08	-	-	8.862E-10	-	-
50	rs4871397	8	124635197	<i>KLHL38</i>	DHS; AA-EAJoint; PR-AFConcordant	1.123E-07	3.165E-10	-	-	3.356E-11	-	-
51	rs1771644	10	31354140	<i>ZNF438</i>	PR-QRSConcordant	-	-	3.025E-08	-	-	-	-
52	rs174545	11	61325882	<i>FADS1</i>	PR-QRSConcordant	-	-	2.638E-08	-	-	-	-
53	rs11839149	13	48801335	<i>CAB39L</i>	PR-QRSConcordant	-	-	1.440E-08	-	-	-	-
54	rs8046873	16	81309433	<i>CDH13</i>	AA-EAJoint	-	3.369E-09	-	-	-	-	-
55	rs1006325	20	39067017	<i>TOP1</i>	PR-RRConcordant	-	-	-	-	-	-	3.965E-08
56	rs11906462	20	60569397	<i>C20orf166</i> <i>NCRNA0011</i>	PR-RRConcordant	-	-	-	-	-	-	1.708E-08
57	rs13047360	21	27773451	3	PR-QRSDiscordant	-	-	-	1.122E-08	-	-	-